|CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.|
|PMID: 22611320 Owner: NLM Status: MEDLINE|
|AIM: To investigate the relationship and molecular features of CD74/macrophage migration inhibitory factor (MIF)/Toll-like receptor 4 (TLR4) in gastric cancer.
METHODS: CD74, MIF and TLR4 expression in the paraffin-embedded sections of gastric cancer from 120 patients were detected by immunohistochemical staining. Knock down of CD74 expression in gastric cancer cell line MKN-45 was performed by lentivirus transduction and detected by Western blotting. MKN-45 cell proliferation assay under the stimulants was measured by the cell counting kit 8 (CCK8) assay and MIF concentration in the culture medium was detected by enzyme-linked immunosorbent assay. Surface staining of CD74 in the MKN-45 cell line under the stimulation of lipopolysaccharide (LPS) was measured by flow cytometry. MIF, CD74 and TLR4 co-localization in the MKN-45 cell line was performed by the immunoprecipitation.
RESULTS: CD74, MIF and TLR4 were found to be expressed in gastric cancer and increased significantly in the advanced stage, and were also associated with lymph node metastasis. Correlation analysis revealed that CD74 was positively correlated with MIF (r = 0.2367, P < 0.01) and both proteins were also associated with TLR4 (r = 0.4414, r = 0.5001, respectively, P < 0.01). LPS can significantly promote MKN-45 cell proliferation (3.027 ± 0.388 vs 4.201 ± 0.092, P < 0.05), induce MIF production (54.333 ± 2.906 pg/mL vs 29.667 ± 3.180 pg/mL, P < 0.01) and cell surface expression of CD74 (75.6% ± 4.046% vs 9.4% ± 0.964%, P < 0.01) at LPS concentration of 1 μg/mL compared to medium control. Knockdown of CD74 or using anti-CD74 and MIF antagonist ISO-1 significantly reduced LPS-induced MKN-45 cell proliferation (4.201 ± 0.092 vs 3.337 ± 0.087, 4.534 ± 0.222 vs 3.368 ± 0.290, 4.058 ± 0.292 vs 2.934 ± 0.197, respectively, P < 0.01). MIF, CD74 and TLR4 could co-localize in the MKN-45 cell line.
CONCLUSION: Upregulation of MIF, CD74 and TLR4 are associated with increasing clinical stage and provide an opportunity as novel gastric cancer chemoprevention and/or treatment strategy.
|Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui|
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: World journal of gastroenterology : WJG Volume: 18 ISSN: 1007-9327 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2012 May|
|Created Date: 2012-05-21 Completed Date: 2012-09-17 Revised Date: 2013-06-24|
Medline Journal Info:
|Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China|
|Languages: eng Pagination: 2253-61 Citation Subset: IM|
|Department of Laboratory Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.|
|APA/MLA Format Download EndNote Download BibTex|
Antigens, Differentiation, B-Lymphocyte
Cell Line, Tumor
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Gene Knockdown Techniques
Histocompatibility Antigens Class II / genetics, metabolism*
Intramolecular Oxidoreductases / antagonists & inhibitors, metabolism*
Isoxazoles / pharmacology
Lipopolysaccharides / pharmacology
Macrophage Migration-Inhibitory Factors / antagonists & inhibitors, metabolism*
Stomach Neoplasms / genetics, immunology*, pathology, therapy
Toll-Like Receptor 4 / metabolism
|0/3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester; 0/Antigens, Differentiation, B-Lymphocyte; 0/Histocompatibility Antigens Class II; 0/Isoxazoles; 0/Lipopolysaccharides; 0/Macrophage Migration-Inhibitory Factors; 0/TLR4 protein, human; 0/Toll-Like Receptor 4; 0/invariant chain; EC 5.3.-/Intramolecular Oxidoreductases; EC 22.214.171.124/MIF protein, human|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antibiotic resistance and cagA gene correlation: a looming crisis of Helicobacter pylori.
Next Document: Preventive effects of geranylgeranylacetone on rat ethanol-induced gastritis.